Uygur M M, Dereli Yazıcı D, Gogas Yavuz D
Deparment of Internal Medicine, Division of Endocrinology and Metabolism, Marmara University School of Medicine, Istanbul, Turkey.
Deparment of Internal Medicine, Division of Endocrinology and Metabolism Diseases, Koc University School of Medicine, Istanbul, Turkey.
J Endocrinol Invest. 2022 Jul;45(7):1405-1412. doi: 10.1007/s40618-022-01775-w. Epub 2022 Mar 25.
Elevated fibroblast growth factor-21 (FGF-21) levels are related to carotid intima-media thickness (CIMT), a well-established marker of atherosclerosis. Acromegaly has also been linked to increased CIMT. There has been no data considering the association between FGF-21 levels and atherosclerosis in acromegaly patients. This study aimed to evaluate FGF-21 levels and CIMT in acromegalic patients in relation to atherosclerotic complications.
Case-control study.
The study group included 70 acromegaly patients and 72 healthy volunteers from the Department of Endocrinology and Metabolism Disease, Marmara University Medical School. FGF-21, growth hormone, insulin-like growth factor I, lipids, glucose, insulin levels were assessed. CIMT was measured from the common carotid artery wall on B-mode ultrasound.
Median FGF-21 levels were significantly lower in the acromegaly group than in the control group. CIMT was higher in acromegaly patients compared to controls. Although there was no correlation between FGF-21 levels and CIMT in patients with acromegaly, a positive correlation was found between high-density lipoprotein-cholesterol and FGF-21 levels. Glucose metabolic markers were the determining factors of the FGF-21 levels in acromegaly patients.
Our study is the first to examine the relationship between serum FGF-21 levels and atherosclerosis in acromegaly patients. The lower serum FGF-21 levels in acromegaly subjects might be associated with the improving effects of growth hormone on liver fat. Acromegaly was linked to higher CIMT, but there was no correlation between FGF-21 levels and CIMT. The role of FGF-21 in acromegaly as a marker of atherosclerosis requires additional research.
成纤维细胞生长因子21（FGF - 21）水平升高与颈动脉内膜中层厚度（CIMT）相关，CIMT是动脉粥样硬化的一个公认标志物。肢端肥大症也与CIMT增加有关。目前尚无关于肢端肥大症患者FGF - 21水平与动脉粥样硬化之间关联的数据。本研究旨在评估肢端肥大症患者的FGF - 21水平和CIMT与动脉粥样硬化并发症的关系。
病例对照研究。
研究组包括来自马尔马拉大学医学院内分泌与代谢疾病科的70例肢端肥大症患者和72名健康志愿者。评估了FGF - 21、生长激素、胰岛素样生长因子I、血脂、血糖、胰岛素水平。通过B型超声测量颈总动脉壁的CIMT。
肢端肥大症组的FGF - 21水平中位数显著低于对照组。肢端肥大症患者的CIMT高于对照组。虽然肢端肥大症患者的FGF - 21水平与CIMT之间无相关性，但发现高密度脂蛋白胆固醇与FGF - 21水平呈正相关。糖代谢标志物是肢端肥大症患者FGF - 21水平的决定因素。
我们的研究首次探讨了肢端肥大症患者血清FGF - 21水平与动脉粥样硬化之间的关系。肢端肥大症患者血清FGF - 21水平较低可能与生长激素对肝脏脂肪的改善作用有关。肢端肥大症与较高的CIMT相关，但FGF - 21水平与CIMT之间无相关性。FGF - 21在肢端肥大症中作为动脉粥样硬化标志物的作用需要进一步研究。
